Vaccentis, a biotech company based in Zurich, Switzerland, has announced a strategic partnership with TrueMed, a leading commercialization partner, to accelerate the development of their therapeutic protein-based tumor vaccines. The agreement, signed on Thursday October 9, 2025, aims to drive the strategic and operational development of Vaccentis, with a focus on their lead vaccine candidate VCC-001 and its platform technology.
VCC-001 is an individualized therapeutic vaccine for the adjuvant treatment of renal cell carcinoma and has shown promising results. Under the agreement, TrueMed will provide support through their established infrastructure and continuous search for potential strategic partnerships. Vaccentis has granted exclusive rights to TrueMed for the commercialization, sale, and distribution of VCC-001 and future pipeline candidates in Israel for the duration of the agreement.
The partnership between Vaccentis and TrueMed brings together their respective expertise in research and development, business development, and strategic alliances, with the aim of advancing the next milestones for VCC-001.
“We are excited about the potential of VCC-001 to revolutionize cancer treatment and are committed to supporting Vaccentis in their mission. With our years of experience in market launch and commercialization, as well as our extensive investor network, we believe we can help bring this vaccine to patients as soon as possible,” say Arie Koren and Shmulik Berkovich, co-CEOs and founders of TrueMed.
Vaccentis CEO Martin Munte and Board Member Patrik Grandits also express their enthusiasm for the collaboration, stating, “TrueMed’s support offers valuable opportunities to accelerate the development of VCC-001 and our tumor vaccine platform technology. As a sparring partner with expertise and a large network in the health-related financial community, TrueMed can help us bring VCC-001 to patients sooner.”
Vaccentis AG specializes in the development and manufacturing of individual cancer vaccines, with a focus on therapeutic individualized tumor vaccines produced from the patient’s own tumor. Their initial focus is on renal cell carcinoma, with plans to expand to other indications in the future. The company expects approval for the EU and USA in the coming years.
TrueMed is a leading commercialization partner for rare disease and specialty care therapies in Israel, providing tailored solutions for global innovators. They have successfully launched innovative technologies in the local market and are committed to delivering complex therapies to patients in need.
For further information, please visit the company’s websites:
Vaccentis – vaccentis.com
TrueMed – www.TrueMedtx.com
For press inquiries, please contact:
Brandenstein Communications
+43 1 319 41 01-11
presse@brandensteincom.at
Distributed by https://pressat.co.uk/